This is an open-label, multi-center, non-randomized, Phase 1/2 study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with active lupus nephritis (LN) or primary membranous nephropathy…
- Investigator
- Michael R Bubb
- Ages
- 18 Years - 70 Years
- Sexes
- All